georgwinter.bsky.social
Chemical Biologist with passion for Cancer Research, Targeted Protein Degradation & Transcription.Scientific Founder of Proxygen & Solgate. Pats Fan. Dad.
winter-lab.com
11 posts
946 followers
161 following
Regular Contributor
comment in response to
post
Thanks, Stephan. Very kind!
comment in response to
post
Thanks & right back to you!
comment in response to
post
Over the next 5 years, we'll work very hard to provide proof of concept and deep mechanistic understanding for this therapeutic modality. Thanks to all current and former group members, mentors and colleagues who helped us to get into this position, we can't wait to get started!
comment in response to
post
welcome to Vienna! let me know when you have set up shop and we can have you over.
comment in response to
post
exactly! T cell ans NK cell activation in addition to the direct targeting of the MM vulnerability.
comment in response to
post
this is a great point, Quinn! I'd argue that IMiDs are also efficacious through non cancer cell-autonomous mechanisms, thereby reducing selective pressure.